Technology firm Rhinomed Limited (ASX:RNO) has been granted a trading halt by the ASX, pending details of a capital raising.
The company has a very unique focus on nasal, respiratory and breathing management technologies, and is focussed on monetising applications for markets including sleep, wellbeing, drug delivery and sport.
Earlier in the month the company entered into a landmark partnership with SleepGP, a growing network of GP practices, to raise awareness of sleep disordered breathing issues within the family medicine setting.
Rhinomed's Mute™ is a unique nasal respiratory technology that has been found to reduce the volume and frequency of snoring in 75% of users.
The halt will remain in place until the opening of trade on Friday 18th September 2015, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.